4-(3-甲氧基苯基)哌啶盐酸盐

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-(3-甲氧基苯基)哌啶盐酸盐
• 英文名称: 4-(3-methoxyphenyl)piperidine hydrochloride
• 英文别名: 4-(3-methoxyphenyl)piperidine hydrogen chloride salt；4-(3-methoxyphenyl)piperidinium chloride；4-(3-methoxyphenyl)piperidine HCl；Hydron;4-(3-methoxyphenyl)piperidine;chloride；hydron;4-(3-methoxyphenyl)piperidine;chloride
• 化学式: C₁₂H₁₇NO*ClH
• mdl: MFCD02178922
• 分子量: 227.734
• InChiKey: UFIHUSFFAGVMDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.92
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.3
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(3-甲氧基苯基)哌啶盐酸盐 在 氢溴酸 作用下， 反应 2.0h， 以89%的产率得到4-(3-羟苯基)哌啶
  参考文献：
  名称：

  New Strong Fibrates with Piperidine Moiety.

  摘要：

  合成并评估了结构中含有哌啶、4-羟基哌啶、哌啶-3-烯和哌嗪分子的新型纤维化合物。在合成的化合物中，2-[3-[1-（4-氟苯甲酰基）-哌啶-4-基]苯氧基]-2-甲基丙酸（9aA : AHL-157）在降低小鼠和大鼠甘油三酯、胆固醇和血糖方面的活性优于贝扎贝特。

  DOI：

  10.1248/cpb.48.1978
• 作为产物：
  描述：

  1-Benzyl-4-(3-methoxy-phenyl)-piperidin-4-ol 在 盐酸 、 甲烷磺酸 、 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醚 、 乙醇 、 乙酸乙酯 、 甲苯 为溶剂， 反应 52.0h， 生成 4-(3-甲氧基苯基)哌啶盐酸盐
  参考文献：
  名称：

  Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6-tetrahydropyridines as 5-HT2C agonists

  摘要：

  A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.01.122

文献信息

• [EN] SUBSTITUTED AMINOQUINOLONES AS DGKALPHA INHIBITORS FOR IMMUNE ACTIVATION<br/>[FR] AMINOQUINOLONES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DGKALPHA POUR ACTIVATION IMMUNITAIRE
  申请人：BAYER AG

  公开号：WO2021105117A1

  公开（公告）日：2021-06-03

  The present invention covers aminoquinolone compounds of general formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8 and n are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment and/or prophylaxis of diseases, in particular of diacylglycerol kinase alpha regulated disorders, as a sole agent or in combination with other active ingredients.

  本发明涵盖了一般式(I)的氨基喹啉酮化合物，其中R1、R2、R3、R4、R5、R6、R7、R8和n如本文所定义，制备所述化合物的方法，用于制备所述化合物的中间化合物，包括所述化合物的药物组合物和组合物，以及利用所述化合物制造用于治疗和/或预防疾病的药物组合物，特别是二酰基甘油激酶α调节性疾病，作为唯一药剂或与其他活性成分组合使用。
• Process for preparing trans-2,4-disubstituted piperidines
  申请人：——

  公开号：US20030092733A1

  公开（公告）日：2003-05-15

  1 The present invention provides a process for preparing a compound of formula (I), wherein R represents C 1 -C 4 alkyl; and X represents an alkyl, alkenyl, cycloalkyl, aryl, substituted aryl, heterocycle, or substituted heterocycle, comprising treating a compound of formula (II), with a suitable crown ether and a suitable base followed by addition of a compound of formula R − M + wherein M + is a suitable cation.

  本发明提供了一种制备式（I）化合物的方法，其中R代表C1-C4烷基；X代表烷基，烯基，环烷基，芳基，取代芳基，杂环或取代杂环，包括用适当的冠醚和适当的碱处理式（II）化合物，随后加入式R-M+的化合物，其中M+是适当的阳离子。
• BENZIMIDAZOLYL COMPOUNDS
  申请人：Efremov Ivan

  公开号：US20080280933A1

  公开（公告）日：2008-11-13

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  本文披露了化合物及其药学上可接受的盐，其中化合物的结构如规范中所定义的I式。还披露了相应的制药组合物、治疗方法、合成方法和中间体。
• AZABENZIMIDAZOLYL COMPOUNDS
  申请人：Efremov Ivan

  公开号：US20080312271A1

  公开（公告）日：2008-12-18

  Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

  该专利公开了化合物及其药学上可接受的盐，其中该化合物的结构式定义如说明书中的式I。同时公开了相应的药物组合物、治疗方法、合成方法和中间体。
• Synthesis and SAR study of 4-arylpiperidines and 4-aryl-1,2,3,6-tetrahydropyridines as 5-HT2C agonists
  作者：Richard J. Conway、Celine Valant、Arthur Christopoulos、Alan D. Robertson、Ben Capuano、Ian T. Crosby

  DOI：10.1016/j.bmcl.2012.01.122

  日期：2012.4

  A series of substituted 4-arylpiperidines and a smaller family of 4-aryl-1,2,3,6-tetrahydropyridines were synthesized and their biological activity at the 5-HT2C receptor studied to determine whether either series showed noteworthy agonist activity. Structure-activity relationships were developed from the performed receptor binding assays and functional studies, and the results of the analysis are presented herein. Crown Copyright (C) 2012 Published by Elsevier Ltd. All rights reserved.